Stock Yards Bank & Trust Co. Sells 3,045 Shares of AbbVie Inc. $ABBV

Stock Yards Bank & Trust Co. trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 5.0% during the 1st quarter, Holdings Channel reports. The institutional investor owned 57,876 shares of the company’s stock after selling 3,045 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in AbbVie were worth $12,587,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Chelsea Counsel Co. purchased a new stake in AbbVie during the third quarter valued at approximately $26,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth approximately $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth approximately $29,000. Imprint Wealth LLC increased its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie during the 3rd quarter valued at approximately $31,000. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ABBV shares. Canaccord Genuity Group raised their price target on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Evercore set a $235.00 target price on shares of AbbVie in a research note on Friday, May 15th. Piper Sandler restated an “overweight” rating and issued a $298.00 target price on shares of AbbVie in a report on Tuesday, June 23rd. Finally, DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $251.07 on Thursday. The firm’s 50 day simple moving average is $217.86 and its 200-day simple moving average is $219.76. AbbVie Inc. has a one year low of $184.63 and a one year high of $255.99. The firm has a market cap of $443.59 billion, a PE ratio of 123.68, a price-to-earnings-growth ratio of 0.83 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the business earned $2.46 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities research analysts predict that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s payout ratio is 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.